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INTRODUCTION 
The rates of sexual dysfunctions among patients with 
PTSD are much higher than in the general population. 
An increasing body of scientific research has confirmed 
clinically relevant sexual problems (Letourneau et al. 
1997, Kotler et al. 2000, Hossain et al. 2013, Yehuda et 
al. 2015, Tran et al. 2015), among which erectile dys-
function (ED) and premature ejaculation (PE) were the 
most frequent (Letourneau et al. 1997). It is important to 
underline that patients, particularly military veterans 
with PTSD, have an increased risk of sexual dysfunc-
tion independent of the use of psychiatric medications 
(Benjamin et al. 2014).  
Considering the utilization of pharmacotherapy, data 
indicate that over 80% of the veterans treated for PTSD 
in the USA have been receiving at least one of the 
psychotropic medications (Bernardy et al. 2012). A drug 
utilization study conducted in Croatia revealed that the 
annual frequency of drug use among pharmacologically 
treated PTSD patients was the highest for anxiolytics 
(75.83% patients), antidepressants (61.36%), hypnotics 
(35.68%) and antipsychotics (30.21%) in 2012 (Letica-
Crepulja et al. 2015). In this context, it is very important 
to highlight that a variety of psychotropic medications 
recommended for the treatment of PTSD can induce 
sexual function disorders (Clayton & Shen 1998, Labbate 
2008). Most practice guidelines for the treatment of 
PTSD highlight antidepressants as the first-line phar-
macotherapeutic agents, particularly selective serotonin 
reuptake inhibitors (SSRIs) (Ballenger et al. 2000, 
American Psychiatric Association 2004, National Insti-
tute for Clinical Excellence (NICE) 2005, Baldwin et al. 
2005, Forbes et al. 2007) and serotonin-norepinephrine 
reuptake inhibitors (SNRIs) (Bandelow et al. 2008, 
Benedek et al. 2009, Stein et al. 2009, Department of 
Veterans Affairs 2010, World Health Organization 
2013, Baldwin et al. 2014). Since the introduction of 
these medications, increasing attention has been given 
to the side effects, such as sexual dysfunction (Labbate 
2008, Corona et al. 2009, Serretti & Chiesa 2011). 
SSRIs can negatively affect all domains of sexuality 
(desire-arousal-orgasm-resolution) (Corona et al. 2009). 
A study of sexual functioning in war veterans with post-
traumatic stress disorder conducted in Croatia showed 
that these patients had less sexual activity, hypoactive 
sexual desire and more frequent ED compared with 
healthy volunteers. These problems might be associated 
with the antidepressant therapy (Antičević & Britvić 
2008). Another Croatian study revealed that the popu-
lation exposed to traumatic event(s) had the same level 
of sexual functioning (or the same incidence of sexual 
dysfunction) regardless of the absence or presence of 
PTSD symptoms and their severity (Arbanas 2010).  
The aim of this report was to present a patient with 
PTSD and comorbid sexual dysfunctions. 
 
CASE REPORT 
The Croatian 47-year-old male war veteran was a 
member of the Special Forces of the Croatian Army 
during the Homeland War (1991-1995) in Croatia. He 
participated in all crucial military actions at the western 
battlefield during the war and was exposed to multiple 
repetitive potentially traumatic events during combat 
and incarceration. He experienced the most stressful 
traumatic event in 1992, when his fellow soldier and he 
were caught in crossfire. His fellow soldier was shot 
dead and left bleeding in the fire-swept zone. Unable to 
help his dying fellow, our patient felt intense fear, 
helplessness and an irresistible urinary urgency. When 
he allowed a flow of urine, he was blocked, dry, not 
even a drop of urine came out of the urethra. After the 
traumatic exposure, he experienced recurrent and intru-
sive distressing recollections of the event, tension with 
vegetative arousal, insomnia and nightmares, startle 
responses to sudden noises accompanied by urinary 
urgency, urinary frequency and PE. He did not ask for 
professional help and was active in the armed forces 
until the end of the war. After military deployment, he 
continued his previous professional employment in the 
police, continually suffering from PTSD-related symp-
toms, urinary and sexual dysfunction. He got married in 
1995, but still has no children. 
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Subsequently, in 2005, he was referred to the regional 
centre for PTSD. During the psychiatric and psycho-
logical assessment, the clinical diagnosis of PTSD was 
supported by the Harvard Trauma Questionnaire (HTQ): 
Croatian Version in the form of a structured interview to 
determine PTSD and the traumatization level (Allden et 
al. 1997). The treatment included participation in a 
psychotherapeutic program in a day hospital during 3 
months, which included psychoeducation, group cogni-
tive – behavioral therapy and trauma-focused group 
treatment in a homogeneous group of war veterans with 
PTSD and continuous psychopharmacological treatment.  
During the subsequent period, he was under out-
patient psychiatric care delivered through approximately 
4 psychiatric controls per year. Psychopharmacologic 
treatment included antidepressants with conversions of 
several different selective serotonin reuptake inhibitors 
(SSRIs), serotonin-norepinephrine reuptake inhibitor 
(SNRI)) prescribed regularly and anxiolytics and hypno-
tics prescribed as needed. In 2011, quetiapine was 
prescribed with the intention to decrease anxiolytics 
utilization and because of the expected therapeutic 
effect on hyperarousal symptoms. However, PE and 
urinary urgency persisted and urological evaluation 
revealed no organic basis for the difficulties.  
Finally, in 2014, he came to the regular control 
expressing his concerns about the adverse effects of the 
therapy. When I encouraged him to talk about his 
satisfaction with his sexual functioning, he revealed 
with great discomfort that he had been suffering from 
PE for years. He explained that he was usually very 
tense and anxious about his sexual performance because 
he could not maintain the time taken to ejaculate during 
vaginal penetration (i.e. the intravaginal ejaculation 
latency time (IELT)) longer than for a few seconds, and 
sometimes he ejaculated even before the penetration. 
His problem was generalized and present even when he 
masturbated. He masturbated rarely and in a compulsory 
manner trying to get it done as quickly as possible just 
to relieve tension. He perceived vegetative hyperarousal 
as a reminder of his traumatic experiences with sub-
sequent intrusive memories, hypervigilance and even 
more anxious feeling. He developed strategies to sup-
press and repress all negative and uncomfortable 
feelings, thoughts and memories and to avoid all the 
reminders as much as he could. His sexual desire was 
decreasing as well as his sexual activity. Due to 
constraints resulting from his traditional cultural 
background, he was unwilling to speak about the 
problems with his wife. Their relationship was stable, 
but insufficient in in-depth communication about inti-
mate issues, feelings, emotional needs, relational 
problems and in particular sexuality. Physical intimacy 
such as kissing, touching, hugging was sparse. The 
patient was also reluctant to engage in any diagnostic or 
therapeutic intervention beyond the acceptance of con-
version of the drugs. For this reason and in view of the 
known ejaculation-delaying effect of paroxetine and its 
scientifically proven therapeutic effects in patients with 
PTSD, this medication was considered the best thera-
peutic option and was administered in a targeted dose of 
30 mg per day. As a result, the patient was calmer, his 
sexual functioning improved, ejaculation was delayed, 
and urinary urgencies became much less frequent than 
in the previous period. However, in December 2014, 
problems with erectile functioning began. He did not 
complain about this until March 2015, when complete 
loss of erection occurred even during the sleep. In that 
period, multimodal antidepressant vortioxetine was 
introduced in the Croatian market and its good charac-
teristics considering the very low incidence of sexual 
dysfunction during the treatment were argument enough 
for choosing this medication. The switching was done 
by cross-tapering with paroxetine during the period of 
10 days with a targeted dose of vortioxetine of 10 mg. 
The patient also used 100mg of quetiapine per day. He 
experienced an improvement of erectile functioning, but 
during the first subsequent sexual intercourse, which 
occurred 20 days after the introduction of the drug, the 
erection continued after the intercourse ended in the 
absence of any physical and psychological stimulation. 
Unfortunately, the priapism was complicated with para-
phimosis. The patient found his troubles humiliating and 
shameful, and giving that the problems occurred during 
the Easter period, he was reluctant to seek medical help. 
He stopped taking vortioxetine immediately. Seven days 
later, the pain was becoming unbearable so he finally 
went to the hospital. Urgent incision of the prepuce was 
performed by the urologist because of the incipient 
necrosis of the glans penis. After the procedure, oral 
antibiotics and daily sterile dressing were administered. 
In the meantime, recommended elective circumcision 
was performed. Several months later, short cognitive-
behavioral therapy was conducted with the focus on 
psychoeducation, overcoming relational obstacles, re-
laxation and distraction techniques. The patient was not 
willing to engage in other psychotherapeutic modalities 
such as sexual therapy and was reluctant to include his 
wife in the therapy, but he accepted to talk about sexu-
ality and the sexual dysfunction with his wife, 
especially after the surgical intervention. His wife and 
he gradually opened to each other expressing their needs 
and willing to improve their relationship, spending 
much more time together and becoming more physically 
intimate. To date, the patient has achieved a substantial 
improvement in his sexual life with periodic worsenings 
(lasting several weeks), particularly during the period of 
the anniversary of the trauma, when he temporarily 
withdrew himself from the social interactions and 
expected to be left alone The patient has provided his 
written informed consent for the publication of this case 
report. 
 
DISCUSSION 
We presented this case to contribute to the dis-
cussion on sexual dysfunction among veterans with 
PTSD. The problem is often overlooked clinically and 
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underexamined in scientific studies. PTSD and sexual 
dysfunction following trauma exposure share many of 
the same neurobiological processes (Yehuda et al. 
2015). In PTSD, the sympathetic nervous system (SNS) 
is in the state of sustained hyperactivity, as evidenced 
by elevations in the heart rate, blood pressure, skin 
conductance, and other psychophysiological measures 
(Sherin & Nemeroff 2011, Yehuda et al. 2015). The 
optimal level of SNS activation is also required for 
healthy sexual functioning. Sexual stimuli activate the 
SNS, increasing the oxygen uptake and blood flow from 
the heart (Lorenz et al. 2012). The appropriate response 
of the hypothalamic-pituitary-adrenal (HPA) axis is 
crucial in the stress response. Although stressors acti-
vate the HPA axis, studies in combat veterans with 
PTSD demonstrate decreases in cortisol concentrations 
(Resnick et al. 1995, Delahanty et al. 2000, Meewisse et 
al. 2007, Bremner et al. 2008). The reduced cortisol 
activity facilitates a prolonged SNS response and in-
creased levels of catecholamines (such as noradrenaline 
or adrenaline) (Yehuda 2009, Sherin & Nemeroff 2014, 
Yehuda et al. 2015). Intrusion symptoms of PTSD such 
as recurrent memories, flashbacks and nightmares are 
directly related to elevated catecholamines as they are 
linked to “overconsolidation” of the traumatic memories 
(Dębiec et al. 2011).  
Sexual stimuli generally produce a decrease in cor-
tisol, allowing increment of catecholamines such as nor-
adrenaline and consequent sexual arousal and activity. 
In patients with PTSD, hyperactivated SNS induce 
overly high levels of catecholamines producing a gene-
ralized fear response that is sexually inhibitory (Gera-
cioti et al. 2001). Serotonin is a monoamine neurotrans-
mitter which is included in the modulation of the HPA 
axis and noradrenaline responses during exposure to 
stress. Decreased serotonergic activity compromises 
anxiolytic effects, increases vigilance, startle, impulsi-
vity, and memory intrusions (Sherin & Nemeroff 2011). 
This is the neurobiological basis for treatment of core 
symptoms of PTSD with SSRI, which are repeatedly 
confirmed by numerous scientific studies as a first-line 
pharmacotherapeutic treatment option. Among other 
medicines from this pharmacological group, paroxetine 
has the most prominent ejaculation-delaying effect (Se-
graves 2006), caused by its impact on serotonergic 
receptors, cholinergic receptor blockade effect and inhi-
bition of nitric oxide synthase (Waldinger et al. 1998, 
Waldinger 2002, Waldinger & Olivier 2005, Rowland et 
al. 2010)  
As a consequence of the processes described above, 
it is probable that our patient got stuck in the interwoven 
neurophysiological pathways of PTSD and sexual dys-
functions. The physiological arousal required in sexual 
activity was not accompanied by inhibition of fear and 
stress response, which could be the reason why every 
sexual arousal was perceived as threat and danger, with 
symptoms of tension, anxiety, hypervigilance and intru-
sion, resulting in the urge to overcome and resolve this 
state with early or premature ejaculation. The applied 
combined treatment had a limited and unsatisfactory 
effect on PTSD symptoms so premature ejaculation 
persisted. Paroxetine with its potent effect on sexual 
functioning could have had a transitory positive de-
laying effect on ejaculation, but adverse effects occur-
red very soon, manifested in complete erectile dys-
function. Vortioxetine, another modulator of seroto-
nergic function, was administered, particularly owing 
to its favorable tolerability profile with regard to low 
sexual dysfunction. Regrettably, the improvement in 
the erectile function was complicated with priapism 
and paraphimosis, but this serious condition was 
gradually overcome by the partners' willingness to 
interact more closely with each other, with the resul-
ting improvement of sexual functioning and reduction 
of PTSD symptoms. 
 
CONCLUSION 
Our case report confirms that PTSD is a complex set 
of multidimensional domains (Jakovljević et al. 2012). 
Although sexual dysfunction is not a specific symptom 
of PTSD, it is a frequent comorbid disorder which re-
quires a transdisciplinary comprehensive treatment ap-
proach. As sexuality is one of the crucial domains of the 
quality of human life further research on the comor-
bidity and treatment of sexual dysfunction and PTSD is 
warranted.  
 
Acknowledgements: None. 
Conflict of interest: None to declare. 
Contribution of individual authors: 
Marina Letica-Crepulja: developed the study concept 
and design; 
Marina Letica-Crepulja, Tanja Grahovac-Juretić, 
Sanja Katalinić, Tomislav Lesica, Ika Rončević-
Gržeta & Tanja Frančišković: performed acquisition 
of data, data analysis and interpretation; 
Marina Letica-Crepulja: drafted the manuscript; 
Marina Letica-Crepulja, Tanja Grahovac-Juretić, 
Sanja Katalinić, Tomislav Lesica, Ika Rončević-
Gržeta & Tanja Frančišković: made the critical 
revision of the manuscript and final approval of the 
version to be published. 
 
References 
1. Allden K, Frančišković T, Lavelle J, Mathias M, McInnnes 
K, Mollica RF, et al.: Harvard trauma manual. Croatian 
veteran version. Harvard Program in Refugee Trauma, 
Cambridge, 1997. 
2. American Psychiatric Association: Practice Guideline for 
the Treatment of Patients with Acute Stress Disorder and 
Posttraumatic Stress Disorder. American Psychiatric 
Association, Arlington Va, 2004. 
Marina Letica-Crepulja, Tanja Grahovac-Juretić, Sanja Katalinić, Tomislav Lesica, Ika Rončević-Gržeta & Tanja Frančišković:  
POSTTRAUMATIC STRESS DISORDER AND COMORBID SEXUAL DYSFUNCTIONS          Psychiatria Danubina, 2017; Vol. 29, No. 2, pp 221-225 
 
 
 224
3. Antičević V & Britvić D: Sexual Functioning in War 
Veterans with Posttraumatic Stress Disorder. Croat Med J 
2008; 49:499–505. 
4. Arbanas G: Does post-traumatic stress disorder carry a 
higher risk of sexual dysfunctions? J Sex Med 2010; 
7:1816–21. 
5. Baldwin DS, Anderson IM, Nutt DJ, Bandelow B, Bond A, 
Davidson JR et al.: Evidence-based guidelines for the 
pharmacological treatment of anxiety disorders: recom-
mendations from the British Association of Psycho-
pharmacology. J Psychopharmacol 2005; 19:567-96. 
6. Baldwin DS, Anderson IM, Nutt DJ, Bandelow B, Bond A, 
Davidson JR et al.: Evidence-based guidelines for the 
pharmacological treatment of anxiety disorders, post-
traumatic stress disorder and obsessive-compulsive 
disorder: A revision of the 2005 guidelines from the 
British Association for Psychopharmacology. J 
Psychopharmacol 2014; 28:403-39. 
7. Ballenger JC, Davidson JR, Lecrubier Y, Nutt DJ, 
Borkovec TD, Rickels K et al.: Consensus statement on 
posttraumatic stress disorder from the International 
Consensus Group on Depression and Anxiety. J Clin 
Psychiatry 2000; 61(suppl 5):60-6. 
8. Bandelow B, Zohar J, Hollander E, Kasper S, Möller HJ: 
World Federation of Societies of Biological Psychiatry 
(WFSBP) guidelines for the pharmacological treatment of 
anxiety, obsessive-compulsive and posttraumatic stress 
disorders – first revision. World J Biol Psychiatry 2008; 
9:248-312. 
9. Benedek DM, Friedman MJ, Zatzick D, Ursano RJ: 
Guideline Watch March 2009: Practice Guidelines for the 
Treatment of Patients With Acute Stress Disorder and 
Posttraumatic Stress Disorder. American Psychiatric 
Association, Arlington Va, 2009. 
10. Bernardy NC, Lund BC, Alexander B, Friedman MJ et al.: 
Prescribing trends in veterans with posttraumatic stress 
disorder. J Clin Psychiatry 2012; 73:297-303. 
11. Bremner JD, Elzinga B, Schmahl C, Vermetten E: 
Structural and functional plasticity of the human brain in 
posttraumatic stress disorder. Prog Brain Res 2008; 
167:171–86. 
12. Breyer BN, Cohen BE, Bertenthal D, Rosen RC, Neylan 
TC, Seal KH: Sexual Dysfunction in Male Iraq and Afgha-
nistan War Veterans: Association with Posttraumatic 
Stress Disorder and Other Combat-Related Mental Health 
Disorders: A Population-Based Cohort Study. J Sex Med 
2014; 11:75–83. 
13. Clayton DO, Shen WW: Psychotropic drug-induced sexual 
function disorders: diagnosis, incidence and management. 
Drug Saf 1998; 19:299-312. 
14. Corona G, Ricca V, Bandini E, Mannucci E, Lotti F, 
Boddi V et al.: Selective serotonin reuptake inhibitor-
induced sexual dysfunction. J Sex Med 2009; 6:1259-6. 
15. Dębiec J, Bush DE, LeDoux JE: Noradrenergic 
enhancement of reconsolidation in the amygdala impairs 
extinction of conditioned fear in rats-a possible 
mechanism for the persistence of traumatic memories in 
PTSD. Depress Anxiety 2011; 28:186-93.  
16. Delahanty DL, Raimonde AJ, Spoonster E: Initial 
posttraumatic urinary cortisol levels predict subsequent 
PTSD symptoms in motor vehicle accident victims. Biol 
Psychiatry2000; 48:940–47.  
17. Department of Veterans Affairs, Department of Defense: 
Clinical Practice Guideline: Management of Post-
Traumatic Stress, version 2.0. US Department of Veterans 
Affairs, Washington DC, 2010. 
18. Foa EB, Keane TM, Friedman MJ, Cohen JA: Effective 
Treatments for PTSD: Practice guidelines from the 
International Society for Traumatic Stress Studies. 
Guilford Press, New York, 2010. 
19. Geracioti TD, Baker DG, Ekhator NN, West SA, Hill KK, 
Bruce AB et al.: CSF norepinephrine concentrations in 
posttraumatic stress disorder Am J Psychiatry 2001; 
158:1227–30. 
20. Forbes D, Creamer M, Phelps A, Bryant R, McFarlane A, 
Devilly GJ et al.: Australian Guidelines for the Treatment 
of Adults With Acute Stress Disorder and Posttraumatic 
Stress Disorder. Aust N Z Psychiatry 2007; 41:637-48. 
21. Hosain GM, Latini DM, Kauth M, Goltz HH, Helmer DA: 
Sexual dysfunction among male veterans returning from 
Iraq and Afghanistan: prevalence and correlates. J Sex 
Med 2013; 10:516-23.  
22. Jakovljević M, Brajković L, Jakšić N, Lončar M, Aukst-
Margetić B, Lasić D: Posttraumatic stress disorders 
(PTSD) from different perspectives: a transdisciplinary 
integrative approach. Psychiatr Danub 2012; 24:246-55. 
23. Kotler M, Cohen H, Aizenberg D, Matar M, Loewenthal 
U, Kaplan Z et al.: Sexual dysfunction in male posttrau-
matic stress disorder patients. Psychother Psychosom 
2000; 69:309-15.  
24. Labbate LA: Psychotropics and sexual dysfunction: the 
evidence and treatments. Adv Psychosom Med 2008; 
29:107-30. 
25. Letica-Crepulja M, Korkut N, Grahovac T, Curać J, 
Lehpamer K, Frančišković T: Drug Utilization Trends in 
Patients With Posttraumatic Stress Disorder in a 
Postconflict Setting: Consistency With Clinical Practice 
Guidelines. J Clin Psychiatry 2015; 76:e1271–6. 
26. Letourneau EJ, Schewe PA, Frueh BC: Preliminary 
evaluation of sexual problems in combat veterans with 
PTSD. J Trauma Stress 1997; 10:125-32.  
27. Lorenz TA, Harte CB, Hamilton LD, Meston CM: 
Evidence for a curvilinear relationship between 
sympathetic nervous system activation and women's 
physiological sexual arousal, Psychophysiology 2012; 
49:111–17.  
28. Meewisse ML, Reitsma JB, de Vries GJ, Gersons BP, Olff 
M: Cortisol and post-traumatic stress disorder in adults: 
systematic review and meta-analysis. Br J Psychiatry 
2007; 191:387–92. 
29. National Institute for Clinical Excellence (NICE): Post-
traumatic stress disorder. The management of PTSD in 
adults and children in primary and secondary care. 
National Clinical Practice Guideline number 26. The 
Royal College of Psychiatrists and the British 
Psychological Society, London, 2005. 
30. Resnick HS, Yehuda R, Pitman RK, Foy DW: Effect of 
previous trauma on acute plasma Cortisol level following 
rape. Am J Psychiatry 1995; 152:1675–77. 
31. Rowland D, McMahon CG, Abdo C, Chen J, Jannini E, 
Waldinger MD et al.: Disorders of Orgasm and 
Ejaculation in Men. J Sex Med 2010; 7:1668–86.  
32. Segraves RT: Rapid ejaculation: a review of nosology, 
prevalence and treatment. Int J Impot Res 2006; 18:24–32. 
33. Serretti A, Chiesa A: Sexual side effects of pharmaco-
logical treatment of psychiatric diseases. Clin Pharmacol 
Ther 2011; 89:142-7. 
Marina Letica-Crepulja, Tanja Grahovac-Juretić, Sanja Katalinić, Tomislav Lesica, Ika Rončević-Gržeta & Tanja Frančišković:  
POSTTRAUMATIC STRESS DISORDER AND COMORBID SEXUAL DYSFUNCTIONS          Psychiatria Danubina, 2017; Vol. 29, No. 2, pp 221-225 
 
 
 225
34. Sherin JE, Nemeroff CB: Post-traumatic stress disorder: 
the neurobiological impact of psychological trauma, 
Dialogues Clin Neurosci 2011; 13:263–78. 
35. Stein DJ, Cloitre M, Nemeroff CB, Nutt DJ, Seedat S, 
Shalev AY et al.: Cape Town consensus on posttraumatic 
stress disorder. CNS Spectr 2009; 41(suppl 1):52-8. 
36. Tran JK, Dunckel G, Teng EJ: Sexual dysfunction in 
veterans with post-traumatic stress disorder. J Sex Med 
2015; 12:847-55.  
37. Waldinger MD, Hengeveld MW, Zwinderman AH, Olivier 
B: Effect of SSRI antidepressants on ejaculation: a 
double-blind randomized placebo-controlled study with 
fluoxetine, fluvoxamine, paroxetine and sertraline. J Clin 
Psychopharmacol 1998; 18:274–81.  
38. Waldinger MD: The neurobiological approach to 
premature ejaculation. J Urol 2002; 168:2359–67.  
39. Waldinger MD, Olivier B: Animal models of premature 
and retarded ejaculation. World J Urol 2005; 23:115–18. 
40. World Health Organization: Guidelines for the 
management of conditions specifically related to stress. 
WHO, Geneva, 2013. 
41. Yehuda R: Status of glucocorticoid alterations in post-
traumatic stress disorder. Ann N Y Acad Sci 2009; 
1179:56–69. 
42. Yehuda R, Lehrner A, Rosenbaum TY: PTSD and Sexual 
Dysfunction in Men and Women. J Sex Med 2015; 
12:1107-19.  
 
 
Correspondence: 
Marina Letica-Crepulja, MD, PhD 
Department for Psychiatry and Psychological Medicine 
University of Rijeka School of Medicine 
Cambierieva 17, 51 000 Rijeka, Croatia 
E-mail: marinalc@medri.uniri.hr 
